Global Cord Blood Revenue Growth Rates (CO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Global Cord Blood Corp  (NYSE: CO)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

CO's Revenue Growth by Quarter and Year

Global Cord Blood's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CO Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 196.12
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 196.12

COs Annual Revenue
Global Cord Blood's Revenue in the fiscal year 2022 $ 196.12 millions
Global Cord Blood's Revenue in the fiscal year 2021 $ 177.00 millions
Global Cord Blood's Revenue in the fiscal year 2020 $ 172.50 millions
Global Cord Blood's Revenue in the fiscal year 2019 $ 147.03 millions
Global Cord Blood's Revenue in the fiscal year 2018 $ 149.34 millions




CO Revenue fourth quarter 2022 Y/Y Growth Comment
Global Cord Blood Corp achieved in the fourth quarter 2022, above Company average Revenue increase of 10.8% year on year, to $ 196.12 millions.

Looking into fourth quarter 2022 results within Healthcare Facilities industry 21 other companies have achieved higher Revenue growth. While Global Cord Blood Corp' s Revenue growth of 10.8% ranks overall at the positon no. 2048 in the fourth quarter 2022.


CO Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December 10.8 % 2.61 % 17.32 % -1.55 %
3rd Quarter September - 17.36 % -7.58 % 23.07 %
2nd Quarter June - - - -
1st Quarter March - - - -
FY   -13.02 % 5.46 % 11.52 % -

Financial Statements
Global Cord Blood's fourth quarter 2022 Revenue $ 196.12 millions CO's Income Statement
Global Cord Blood's fourth quarter 2021 Revenue $ 177.00 millions Quarterly CO's Income Statement


CO Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 265.1 % 317.57 % 228.93 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -13.02 % 5.46 % 11.52 % -


Back to CO Growth rate Comparisons >> Back to CO Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #22
Healthcare Sector #309
Overall #2048

Revenue Y/Y Growth Statistics
High Average Low
40.21 % -11.03 % -100 %
(Mar 31 2013)   0
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #22
Healthcare Sector #309
Overall #2048
Revenue Y/Y Growth Statistics
High Average Low
40.21 % -11.03 % -100 %
(Mar 31 2013)   0

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Global Cord Blood's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CO's IV. Quarter Q/Q Revenue Comment


Global Cord Blood's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Mar 31 2018)
Cumulative Revenue 12 Months Ending $ 196.12 $ 177.00 $ 172.50 $ 147.03 $ 149.34
Y / Y Revenue Growth (TTM) 10.8 % 2.6 % 17.32 % -1.55 % 35.26 %
Year on Year Revenue Growth Overall Ranking # 1218 # 0 # 0 # 0 # 3000
Seqeuential Revenue Change (TTM) 10.8 % 2.6 % 17.32 % -1.55 % 35.26 %
Seq. Revenue Growth (TTM) Overall Ranking # 1218 # 0 # 0 # 0 # 3000


Cumulative Revenue growth Comment
Although Global Cord Blood's Annual Revenue growth year on year were below company's average 21.2% , Revenue announced in the Mar 31 2022 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.8% year on year, from 2.6% in Mar 31 2021.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1218.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 13
Healthcare Sector # 203
Overall # 1218

Revenue TTM Y/Y Growth Statistics
High Average Low
118.48 %
 21.2 %
-1.55 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 203
S&P 500 # 1218
Cumulative Revenue growth Comment
Although Global Cord Blood's Annual Revenue growth year on year were below company's average 21.2% , Revenue announced in the Mar 31 2022 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.8% year on year, from 2.6% in Mar 31 2021.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1218.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 13
Healthcare Sector # 203
Overall # 1218

Revenue TTM Y/Y Growth Statistics
High Average Low
118.48 %
21.2 %
-1.55 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 203
S&P 500 # 1218




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CO's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Biolife Solutions Inc 18.64%$ 18.641 millions
Puma Biotechnology Inc 18.64%$ 18.639 millions
Astrazeneca Plc18.53%$ 18.532 millions
United Therapeutics Corporation18.38%$ 18.377 millions
23andme Holding Co17.66%$ 17.664 millions
Clene Inc 17.59%$ 17.588 millions
Guardant Health Inc 17.37%$ 17.374 millions
Viemed Healthcare Inc 17.35%$ 17.352 millions
Amneal Pharmaceuticals Inc 17.30%$ 17.296 millions
Strata Skin Sciences Inc17.06%$ 17.059 millions
Ensign Group Inc16.79%$ 16.792 millions
Dexcom Inc 16.76%$ 16.757 millions
Exact Sciences Corporation16.71%$ 16.712 millions
Elutia Inc 16.61%$ 16.610 millions
Aspira Women s Health inc 16.32%$ 16.316 millions
Neuropace Inc 16.30%$ 16.295 millions
Ispecimen inc 16.18%$ 16.181 millions
Surgery Partners Inc 15.88%$ 15.880 millions
Inovio Pharmaceuticals Inc 15.81%$ 15.811 millions
Inogen Inc 15.30%$ 15.298 millions
Teladoc Health Inc 15.06%$ 15.061 millions
Axogen inc 14.67%$ 14.672 millions
Merck and Co Inc 14.60%$ 14.601 millions
Electromed Inc 14.45%$ 14.452 millions
Ocular Therapeutix Inc 14.36%$ 14.355 millions
Cyclerion Therapeutics Inc 14.29%$ 14.286 millions
Radnet Inc 14.26%$ 14.259 millions
Nabriva Therapeutics Plc14.15%$ 14.145 millions
Aim Immunotech Inc 14.00%$ 14.000 millions
Acutus Medical Inc 13.76%$ 13.755 millions


About Global Cord Blood Revenue Growth Rates (CO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Global Cord Blood Corp (CIK 1467808).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-22-091776
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Global Cord Blood Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.